Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Metastatic Differentiated Thyroid Cancers
Authors:
- Claire SchvartzCSClaire Schvartz
- Cécile DalbanCDCécile Dalban
- Sofiane GuendouzenSGSofiane Guendouzen
- Jean-Marie PochartJPJean-Marie Pochart
- Audrey DalacADAudrey Dalac
- Sandrine FieffeSFSandrine Fieffe
- Claire Bruna-MurailleCBClaire Bruna-Muraille
- Tienhan Sandrine Dabakuyo-YonliTDTienhan Sandrine Dabakuyo-Yonli
- Dimitri PapathanassiouDPDimitri Papathanassiou
- 1 June 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 40 (6) , 469-475
Abstract
To evaluate the prognostic value of F-fluorodeoxyglucose positron emission tomography (FDG PET) with quantitative analysis using metabolic parameters in metastatic differentiated thyroid cancer (DTC). The FDG-PET scans of 37 patients with metastatic DTC were studied retrospectively. The number of FDG-avid lesions, the SUVmax, the SULpeak of the lesion with the highest FDG uptake, the overall metabolic tumor volume (MTV), and the total lesion glycolysis (TLG) were measured. Curves of progression-free survival (Kaplan-Meier) and Cox univariate and multivariate analyses determined the prognostic factors for survival. Progression-free survival was better in patients with less than 10 FDG-avid lesions (P = 0.0089), the SUVmax less than 10 (P = 0.0026), the SULpeak less than 5 (P = 0.0004), and the TLG less than 154 (P = 0.0110).Cox analyses showed that only the result of the PET scan was predictive of survival (age, TNM stage, histology, and the I whole body radioiodine scan were not associated with prognosis). In the univariate analysis, prognostic factors for progression-free survival and overall survival were the SUVmax (P = 0.004; P = 0.018), the SULpeak (P = 0.001; P = 0.017), and the TLG (P = 0.014; P = 0.012). The number of FDG-avid lesions was significantly associated with progression-free survival (P = 0.012), but not the MTV. In the multivariate analysis, the number of FDG-avid lesions and the SULpeak were independent prognostic factors. FDG PET using metabolic parameters is a prognostic factor in metastatic DTC. It could improve the therapeutic management and follow-up of patients.Keywords
This publication has 39 references indexed in Scilit:
- Clinical Utility of 18F-FDG PET/CT Concurrent with 131I Therapy in Intermediate–to–High-Risk Patients with Differentiated Thyroid Cancer: Dual-Center Experience with 286 PatientsJournal of Nuclear Medicine, 2013
- Prognostic Significance of FDG PET/CT on the Follow-Up of Patients of Differentiated Thyroid Carcinoma With Negative 131I Whole-Body Scan and Elevated Thyroglobulin LevelsClinical Nuclear Medicine, 2012
- Positron emission tomography–computed tomography evaluation for recurrent differentiated thyroid carcinomaEuropean Annals of Otorhinolaryngology, Head and Neck Diseases, 2012
- 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancerAnnals of Nuclear Medicine, 2011
- Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative 131I whole body scan: evaluation by thyroglobulin levelAnnals of Nuclear Medicine, 2011
- ML Segmentation Strategies for Object Interference Compensation in FDG-PET Lesion QuantificationMethods of Information in Medicine, 2010
- Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysisNuclear Medicine Communications, 2009
- Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual AnalysisJournal of Nuclear Medicine, 2007
- 3D volume and SUV analysis of oncological PET studiesNuklearmedizin-Nuclear Medicine, 2007